AI Analysis
AI-generated analysis. Always verify with the original filing.
Operating Income was -$241.2M (8.5%) Net Income was -$236.9M (2.8%) Eps was $-1.45 (5.2%)
Key Takeaways
1Operating income improved to -$241.2M, 8.5% narrowing from prior year, signaling R&D efficiency gains through program completions.
2Net income loss narrowed to -$236.9M, a 2.8% improvement year-over-year, driven by ongoing cost controls in a pre-revenue biotech.
3Diluted EPS improved to -$1.45, 5.2% better than -$1.53 prior year, reflecting per-share loss reduction amid clinical investments.
4Net cash used in operations increased to -$206.4M from -$182.9M as the Company funds development without product revenue.